121 related articles for article (PubMed ID: 11885733)
1. Meningococcal vaccination for adolescents? An economic evaluation in Victoria.
Skull SA; Butler JR
J Paediatr Child Health; 2001 Oct; 37(5):S28-33. PubMed ID: 11885733
[TBL] [Abstract][Full Text] [Related]
2. Should programmes for community-level meningococcal vaccination be considered in Australia? An economic evaluation.
Skull SA; Butler JR; Robinson P; Carnie J
Int J Epidemiol; 2001 Jun; 30(3):571-8; discussion 578-9. PubMed ID: 11416085
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
[TBL] [Abstract][Full Text] [Related]
4. Vaccinating first-year college students living in dormitories for Meningococcal disease: an economic analysis.
Scott RD; Meltzer MI; Erickson LJ; De Wals P; Rosenstein NE
Am J Prev Med; 2002 Aug; 23(2):98-105. PubMed ID: 12121797
[TBL] [Abstract][Full Text] [Related]
5. Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.
Bos JM; Rümke HC; Welte R; Spanjaard L; van Alphen L; Postma MJ
Pharmacoeconomics; 2006; 24(2):141-53. PubMed ID: 16460135
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Meningococcal Vaccination Among Men Who Have Sex With Men in New York City.
Simon MS; Weiss D; Geevarughese A; Kratz MM; Cutler B; Gulick RM; Zucker JR; Varma JK; Schackman BR
J Acquir Immune Defic Syndr; 2016 Feb; 71(2):146-54. PubMed ID: 26334735
[TBL] [Abstract][Full Text] [Related]
7. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France.
Lecocq H; Parent du Châtelet I; Taha MK; Lévy-Bruhl D; Dervaux B
Vaccine; 2016 Apr; 34(19):2240-50. PubMed ID: 27002504
[TBL] [Abstract][Full Text] [Related]
8. Health impact and cost-effectiveness of introducing the vaccine (Bexsero) against MenB disease into the Brazilian immunization programme.
Moura Silveira M; McBride AJA; Trotter CL
Vaccine; 2019 Oct; 37(45):6783-6786. PubMed ID: 31570182
[TBL] [Abstract][Full Text] [Related]
9. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
[TBL] [Abstract][Full Text] [Related]
10. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.
De Wals P; Coudeville L; Trottier P; Chevat C; Erickson LJ; Nguyen VH
Vaccine; 2007 Jul; 25(29):5433-40. PubMed ID: 17560695
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada.
Tu HA; Deeks SL; Morris SK; Strifler L; Crowcroft N; Jamieson FB; Kwong JC; Coyte PC; Krahn M; Sander B
Vaccine; 2014 Sep; 32(42):5436-46. PubMed ID: 25131732
[TBL] [Abstract][Full Text] [Related]
12. Cost Effectiveness of Meningococcal Serogroup B Vaccination in College-Aged Young Adults.
Leeds IL; Namasivayam V; Bamogo A; Sankhla P; Thayer WM
Am J Prev Med; 2019 Feb; 56(2):196-204. PubMed ID: 30573332
[TBL] [Abstract][Full Text] [Related]
13. Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis.
Whittles LK; Didelot X; White PJ
Lancet Infect Dis; 2022 Jul; 22(7):1030-1041. PubMed ID: 35427491
[TBL] [Abstract][Full Text] [Related]
14. Challenges and opportunities for meningococcal vaccination in the developing world.
Shaker R; Fayad D; Dbaibo G
Hum Vaccin Immunother; 2018 May; 14(5):1084-1097. PubMed ID: 29393729
[TBL] [Abstract][Full Text] [Related]
15. Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales.
Trotter CL; Edmunds WJ
BMJ; 2002 Apr; 324(7341):809. PubMed ID: 11934772
[TBL] [Abstract][Full Text] [Related]
16. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
[TBL] [Abstract][Full Text] [Related]
17. Health economics of a hexavalent meningococcal outer-membrane vesicle vaccine in children: potential impact of introduction in the Dutch vaccination program.
Bos JM; Rümke HC; Welte R; Postma MJ; Jager JC
Vaccine; 2001 Oct; 20(1-2):202-7. PubMed ID: 11567765
[TBL] [Abstract][Full Text] [Related]
18. Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysis.
Gasparini R; Landa P; Amicizia D; Icardi G; Ricciardi W; de Waure C; Tanfani E; Bonanni P; Lucioni C; Testi A; Panatto D
Hum Vaccin Immunother; 2016 Aug; 12(8):2148-2161. PubMed ID: 27163398
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making.
Welte R; van den Dobbelsteen G; Bos JM; de Melker H; van Alphen L; Spanjaard L; Rümke HC; Postma MJ
Vaccine; 2004 Dec; 23(4):470-9. PubMed ID: 15530695
[TBL] [Abstract][Full Text] [Related]
20. Cost-utility analysis of a nationwide vaccination programme against serogroup B meningococcal disease in Israel.
Ginsberg GM; Block C; Stein-Zamir C
Int J Public Health; 2016 Jul; 61(6):683-692. PubMed ID: 27105884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
